In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
AI and market research sampling: battling bots and biases
Introduction and how the sampling industry works The landscape of market research sampling has had to evolve significantly in recent years. AI-driven bots are...